vs
合众银行（FSBC）与Health Catalyst, Inc.（HCAT）财务数据对比。点击上方公司名可切换其他公司
Health Catalyst, Inc.的季度营收约是合众银行的1.7倍（$74.7M vs $45.1M），合众银行净利率更高（41.3% vs -121.9%，领先163.2%），过去两年合众银行的营收复合增速更高（21.3% vs -0.0%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse，原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征（LEMS）的治疗，2018年11月又获批可用于6岁及以上儿童LEMS患者。
FSBC vs HCAT — 直观对比
营收规模更大
HCAT
是对方的1.7倍
$45.1M
净利率更高
FSBC
高出163.2%
-121.9%
两年增速更快
FSBC
近两年复合增速
-0.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $74.7M |
| 净利润 | $18.6M | $-91.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -115.3% |
| 净利率 | 41.3% | -121.9% |
| 营收同比 | — | -6.2% |
| 净利润同比 | 42.0% | -340.3% |
| 每股收益（稀释后） | $0.87 | $-1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCHCAT
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $74.7M | ||
| Q3 25 | $41.3M | $76.3M | ||
| Q2 25 | $38.3M | $80.7M | ||
| Q1 25 | $35.3M | $79.4M | ||
| Q4 24 | $35.2M | $79.6M | ||
| Q3 24 | $31.8M | $76.4M | ||
| Q2 24 | $30.7M | $75.9M |
净利润FSBCHCAT
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $-91.0M | ||
| Q3 25 | $16.3M | $-22.2M | ||
| Q2 25 | $14.5M | $-41.0M | ||
| Q1 25 | $13.1M | $-23.7M | ||
| Q4 24 | $13.3M | $-20.7M | ||
| Q3 24 | $10.9M | $-14.7M | ||
| Q2 24 | $10.8M | $-13.5M |
毛利率FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 52.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 47.5% | ||
| Q2 24 | — | — |
营业利润率FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -115.3% | ||
| Q3 25 | 53.8% | -22.9% | ||
| Q2 25 | 52.4% | -46.0% | ||
| Q1 25 | 52.0% | -25.4% | ||
| Q4 24 | 55.1% | -22.0% | ||
| Q3 24 | 48.0% | -17.9% | ||
| Q2 24 | 49.4% | -20.8% |
净利率FSBCHCAT
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | -121.9% | ||
| Q3 25 | 39.6% | -29.1% | ||
| Q2 25 | 37.9% | -50.8% | ||
| Q1 25 | 37.1% | -29.9% | ||
| Q4 24 | 37.9% | -26.0% | ||
| Q3 24 | 34.4% | -19.3% | ||
| Q2 24 | 35.2% | -17.8% |
每股收益（稀释后）FSBCHCAT
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $-1.29 | ||
| Q3 25 | $0.77 | $-0.32 | ||
| Q2 25 | $0.68 | $-0.59 | ||
| Q1 25 | $0.62 | $-0.35 | ||
| Q4 24 | $0.61 | $-0.33 | ||
| Q3 24 | $0.52 | $-0.24 | ||
| Q2 24 | $0.51 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $95.7M |
| 总债务越低越好 | — | $153.3M |
| 股东权益账面价值 | $458.5M | $245.8M |
| 总资产 | $5.0B | $502.6M |
| 负债/权益比越低杠杆越低 | — | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资FSBCHCAT
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $95.7M | ||
| Q3 25 | — | $91.5M | ||
| Q2 25 | — | $97.3M | ||
| Q1 25 | — | $342.0M | ||
| Q4 24 | — | $392.0M | ||
| Q3 24 | — | $387.3M | ||
| Q2 24 | — | $308.3M |
总债务FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | — | $153.3M | ||
| Q3 25 | — | $153.1M | ||
| Q2 25 | — | $153.0M | ||
| Q1 25 | — | $382.9M | ||
| Q4 24 | — | $382.4M | ||
| Q3 24 | — | $345.0M | ||
| Q2 24 | — | — |
股东权益FSBCHCAT
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $245.8M | ||
| Q3 25 | $431.3M | $331.9M | ||
| Q2 25 | $416.7M | $347.5M | ||
| Q1 25 | $406.5M | $376.8M | ||
| Q4 24 | $396.6M | $365.2M | ||
| Q3 24 | $389.9M | $355.0M | ||
| Q2 24 | $380.5M | $357.0M |
总资产FSBCHCAT
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $502.6M | ||
| Q3 25 | $4.6B | $587.1M | ||
| Q2 25 | $4.4B | $616.2M | ||
| Q1 25 | $4.2B | $891.5M | ||
| Q4 24 | $4.1B | $858.9M | ||
| Q3 24 | $3.9B | $813.0M | ||
| Q2 24 | $3.6B | $691.7M |
负债/权益比FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 1.05× | ||
| Q3 24 | — | 0.97× | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $9.6M |
| 自由现金流率自由现金流/营收 | — | 12.9% |
| 资本支出强度资本支出/营收 | — | 0.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-697.0K |
8季度趋势，按日历期对齐
经营现金流FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $9.9M | ||
| Q3 25 | $18.8M | $-464.0K | ||
| Q2 25 | $17.8M | $-9.0M | ||
| Q1 25 | $15.5M | $280.0K | ||
| Q4 24 | $51.8M | $-3.5M | ||
| Q3 24 | $17.5M | $6.2M | ||
| Q2 24 | $16.0M | $1.6M |
自由现金流FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | $9.6M | ||
| Q3 25 | $18.6M | $-719.0K | ||
| Q2 25 | $17.5M | $-9.2M | ||
| Q1 25 | $15.4M | $-390.0K | ||
| Q4 24 | $51.2M | $-3.9M | ||
| Q3 24 | $17.3M | $5.5M | ||
| Q2 24 | $15.8M | $1.3M |
自由现金流率FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | 12.9% | ||
| Q3 25 | 45.0% | -0.9% | ||
| Q2 25 | 45.8% | -11.4% | ||
| Q1 25 | 43.5% | -0.5% | ||
| Q4 24 | 145.5% | -4.9% | ||
| Q3 24 | 54.5% | 7.2% | ||
| Q2 24 | 51.6% | 1.7% |
资本支出强度FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 0.4% | ||
| Q3 25 | 0.5% | 0.3% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 1.8% | 0.5% | ||
| Q3 24 | 0.7% | 0.9% | ||
| Q2 24 | 0.7% | 0.4% |
现金转化率FSBCHCAT
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |
